Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAeterna Zentaris Inc

Aeterna Zentaris Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2024-11-11T04:19:37.431765Z
Market Cap
12.77M

Momentum Score

…

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.91
Low
5.18
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
6.86M
Revenue Per Share
1.41
Gross Profit TTM
5.17M
Debt / Equity
0.01
ROE
-61.74%
Net Debt
-50.43M
ROCE
-31.14%
Diluted EPS TTM
-6.49

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -22.73M -8.48M -4.72M -6.23M 9.64M
Net income -30.20M -8.37M -5.12M -6.04M 4.19M
Selling general administrative 8.23M 5.92M 4.76M 6.62M 8.89M
Selling and marketing expenses 8.23M 1.35M 1.13M 1.21M 3.11M
Gross profit 5.48M 5.17M 1.33M 0.12M 24.78M
Reconciled depreciation 0.14M 0.14M 0.23M 0.32M 0.06M
Ebit -15.25M -8.67M -6.06M -9.54M 9.64M
Ebitda -7.65M -8.53M -7.91M -9.23M 9.70M
Depreciation and amortization 7.61M 0.14M -1.84M 0.32M 0.06M
Operating income -15.25M -8.67M -6.06M -9.54M 9.84M
Other operating expenses 20.89M 13.93M 9.72M 10.08M 17.04M
Interest expense 0.00M 0.02M 3.42M 0.59M 0.00M
Tax provision 0.00M -0.11M 0.40M -0.19M 5.45M
Interest income 0.88M 0.21M 1.70M 4.61M 0.92M
Net interest income -0.00M -0.02M -0.74M -0.59M 0.28M
Income tax expense 7.47M -0.11M 0.40M -0.19M 5.45M
Total revenue 5.64M 5.26M 3.65M 0.53M 26.88M
Total operating expenses 20.74M 13.84M 7.40M 9.67M 14.94M
Cost of revenue 0.16M 0.09M 2.32M 0.41M 2.10M
Total other income expense net -7.47M 0.19M 1.34M 3.31M -0.20M
Net income from continuing ops -22.73M -8.37M -5.12M -6.04M 4.19M
Net income applicable to common shares -22.73M -8.37M -5.12M -6.04M 4.19M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 56.03M 80.10M 37.28M 19.98M 25.01M
Intangible assets 0.00M 0.62M 0.06M 0.04M 0.06M
Other current assets 2.49M 1.77M 0.87M 1.21M 1.21M
Total liab 20.25M 27.12M 24.07M 22.44M 23.10M
Total stockholder equity 35.78M 52.99M 13.21M -2.46M 1.91M
Other current liab 1.94M 1.89M 3.00M 2.93M 2.57M
Common stock 293.41M 293.41M 235.01M 224.53M 222.34M
Capital stock 293.41M 293.41M 235.01M 224.53M 222.34M
Retained earnings -352.08M -334.62M -322.66M -316.89M -309.78M
Other liab - 19.32M 19.00M 16.53M 17.51M
Good will 0.00M 8.13M 8.81M 8.05M 8.21M
Other assets 0.32M 0.34M 0.34M 0.36M 0.42M
Cash 50.61M 65.30M 24.27M 7.84M 14.51M
Cash and equivalents 0.00M 9.70M 0.35M 7.84M 14.51M
Total current liabilities 7.04M 7.77M 5.01M 5.66M 5.60M
Current deferred revenue 2.95M 4.82M 2.19M 0.99M 0.07M
Net debt -50.43M -65.14M -24.09M -6.93M -14.51M
Short term debt 0.11M 0.13M 0.14M 0.65M 0.00M
Short long term debt total 0.18M 0.16M 0.18M 0.90M -
Other stockholder equity 95.42M 94.87M 101.91M 89.81M 89.34M
Property plant equipment 0.22M 0.19M 0.18M 0.62M 0.07M
Total current assets 55.49M 70.82M 27.89M 10.91M 16.26M
Net tangible assets - 44.23M 4.34M -10.55M -6.37M
Net receivables 2.16M 3.67M 1.68M 0.66M 0.29M
Inventory 0.23M 0.07M 0.02M 1.20M 0.24M
Accounts payable 2.04M 0.93M 1.19M 1.09M 1.28M
Accumulated other comprehensive income -0.97M -0.68M -1.04M 0.09M 0.01M
Common stock total equity - - 235.01M 224.53M 222.34M
Non currrent assets other 0.32M 0.34M 0.34M 0.36M 0.42M
Non current assets total 0.54M 9.28M 9.39M 9.07M 8.76M
Capital lease obligations 0.18M 0.16M 0.18M 0.90M -
Long term debt total 0.07M 0.03M 0.05M 0.26M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01M -0.66M 0.06M 0.05M -0.04M
Change to liabilities - 3.64M 3.08M 0.13M -0.19M
Total cashflows from investing activities -0.01M -0.66M 0.06M 0.05M -0.04M
Net borrowings - -0.13M -0.27M -0.61M -0.61M
Total cash from financing activities -0.12M 51.04M 20.47M 3.89M 3.89M
Change to operating activities - -1.10M -1.23M -1.04M -1.85M
Net income -22.73M -8.37M -5.12M -6.04M 4.19M
Change in cash -14.69M 41.03M 16.43M -6.67M 6.73M
Begin period cash flow 65.30M 24.27M 7.84M 14.51M 7.78M
End period cash flow 50.61M 65.30M 24.27M 7.84M 14.51M
Total cash from operating activities -13.68M -8.58M -4.13M -10.72M 6.83M
Issuance of capital stock 0.00M 34.20M 23.50M 4.99M 0.00M
Depreciation 0.14M 0.14M 0.23M 0.32M 0.06M
Other cashflows from investing activities -0.00M -0.02M 0.05M 0.05M -0.05M
Change to inventory -0.16M -0.06M 1.18M -0.97M 0.31M
Change to account receivables - 0.12M -1.33M -0.73M -0.10M
Sale purchase of stock 0.00M 54.29M 23.50M 5.30M 0.00M
Other cashflows from financing activities 0.02M 16.96M -2.77M -0.48M -0.04M
Change to netincome - -2.86M -2.38M -3.10M 2.73M
Capital expenditures 0.01M 0.64M 0.03M 0.03M 0.01M
Change in working capital 0.60M 2.50M 2.40M -2.44M -0.15M
Stock based compensation 0.54M 0.31M 0.06M 0.79M 0.57M
Other non cash items 7.76M -3.17M -1.71M -3.35M -1.32M
Free cash flow -13.69M -9.22M -4.13M -10.72M 6.82M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EPRX
Eupraxia Pharmaceuticals Inc		 -0.22
2.32%		 9.26 - - - 8.45 - -3.88
FRX
Fennec Pharmaceuticals Inc		 -1.17
8.09%		 13.29 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -0.40
4.30%		 8.91 - - - 5.85 - 6.47
HBP
Helix BioPharma Corp.		 -0.02
2.17%		 0.90 - 3.87 4263.36 9.74 4422.35 -6.36

Profile*

Aeterna Zentaris Inc

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

315 Sigma Drive, Summerville, SC, United States, 29486

843 900 3223

https://www.zentaris.com

Name Title Year Born
Dr. Klaus Paulini Ph.D. Pres, CEO & Exec. Director NA
Dr. Nicola Ammer M.D. Chief Medical Officer & Sr. VP of Clinical Devel. NA
Dr. Matthias Gerlach Sr. VP Manufacturing & Supply Chain NA
Mr. Giuliano La Fratta Sr. VP of Fin. & CFO NA
Dr. Michael Teifel Sr. VP of Non-Clinical Devel. & Chief Scientific Officer NA
Dr. Eckhard G. Guenther Ph.D. Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany NA
Ms. Amélie Métivier Assistant Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…